主持或参加多项国家自然科学基金及省市级课题，在Nature communication等国际期刊发表SCI论文二十余篇，累计影响因子六十多分🕴，谷歌学术总引用达200次🧚🏿♀️🆙，单篇最高被引156次。
Professor Xu has hosted or participated in a number of national natural science foundation of China, provincial and municipal projects. She has published more than 20 SCI papers in international journals such as Nature Communication, with a total impact factor of more than 60. She has been cited 200 times in Google Academic, and the highest single paper has been cited 156 times.
科研项目🏜：
1、上海市科学技术委员会医学创新研究专项项目，21Y11907000，基于深度学习和类器官模型建立子宫颈癌预后风险模型的临床研究🍞🧑🏼🚒，2021/10-2024/09，30万元，主持🛀🏼，在研。
2🧑🏿🦳、上海市自然科学基金项目，21ZR1450900💆♂️，NAD+代谢介导STING通路增强卵巢癌CD8+T细胞抗肿瘤活性的机制研究🌼，2021/07-2024/06，20万元🫱，主持，在研。
3💇🏿、上海申康临床研究培育项目，SHDC12019X34，烟酸治疗卵巢早衰的临床研究，2019/11-2022/11，10万元🕎，主持，在研。
4👩🏻🔬🙌🏽、国家自然科学基金项目面上项目，81772762，lncRNA IL21-AS1经外泌体诱导肿瘤免疫逃逸微环境致卵巢癌铂类耐药的机制研究👩🏽⚕️，2018/01-2021/12👼🏿，57万元🤢，主持🫔🍿，已结题👨👦。
5、国家自然科学基金项目青年项目，81502227，miR-497双重靶向抑制Akt/mTOR/P70s6k信号通路逆转卵巢癌顺铂耐药的机制研究，2016/01-2018/12，19.2万元，主持，已结题。
6🧜🏽⇾、江苏省南京医科大学科技发展基金重点项目🧜🏽，2011NJMU2311，miR-200a、miR-141的DNA甲基化模式与卵巢癌的相关性研究，2012/01-2014/12，3万元🧦，主持，已结题🧐。
7、 江苏省常州市卫生局重大科研项目🚹，ZD201113🦻🏼，microRNA-200家族在卵巢癌中表达和作用机制的研究，2011/01-2013/12💃🏼，15万元，主持，已结题🤬。
Scientific Research Project:
1. Medical innovation Research special project of Shanghai Science and Technology Commission, 21Y11907000, Clinical study on establishing prognostic risk model of cervical cancer based on deep learning and organoid model, 2021/10-2024/09, 300,000, Leader, under research.
2. Shanghai Natural Science Foundation project, 21ZR1450900, Study on the mechanism of NAD+ metabolism mediated STING pathway enhancing anti-tumor activity of CD8+ T cells in ovarian cancer, 2021/07-2024/06, 200,000, Leader, under research.
3. Shanghai Shenkang Clinical Research Cultivation Project, SHDC12019X34, Clinical study of niacin in the treatment of premature ovarian failure, 2019/11-2020/11, 100, 000, Leader, under research.
4. National Natural Science Foundation of China, 81772762, Exosome-Transmitted lncRNA IL21-AS1 Promotes chemoresistance in Ovarian cancer by rugulating immune evasion, 2018/01-2020/12, 570,000, Leader, completed.
5. National Natural Science Foundation of China, 81502227, The mechanism of miR-497 overcomes cisplatin resistance in ovarian cancer via dual targeting of Akt/mTOR/P70s6k pathway, 2016/01-2018/12, 192,000, Leader, completed.
6. Key Project of Science and Technology Development Fund of Nanjing Medical University, 2011NJMU2311, Correlation between DNA methylation patterns of Mir-200a and Mir-141 and ovarian cancer, 2012/01-2014/12, 30,000, Leader, completed.
7. Key Scientific Research Project of Changzhou Health Bureau of Jiangsu Province, ZD201113, MicrorNA-200 family expression and mechanism of action in ovarian cancer, 2011/01-2013/12, 150, 000, Leader, completed.
主要论著（Main Works）：
1. Zou C, Xu F, Shen J, Xu S*. Identification of a Ferroptosis-Related Prognostic Gene PTGS2 Based on Risk Modeling and Immune Microenvironment of Early-Stage Cervical Cancer. J Oncol. 2022; 2022:3997562.
2. Liu T, Shen J, He Q, Xu S*. Identification of a Novel Immune-Related lncRNA CTD-2288O8.1 Regulating Cisplatin Resistance in Ovarian Cancer Based on Integrated Analysis. Frontiers in genetics. 2022; 13:814291.
3.Shen J, Liu T, Lv J, Xu S*. Identification of an Immune-Related Prognostic Gene CLEC5A Based on Immune Microenvironment and Risk Modeling of Ovarian Cancer. Frontiers in cell and developmental biology. 2021; 9:746932.
4. Xu F, Liu T, Zhou Z, Zou C, Xu S*. Comprehensive Analyses Identify APOBEC3A as a Genomic Instability-Associated Immune Prognostic Biomarker in Ovarian Cancer. Front Immunol. 2021; 12:749369.
5. Shen J, Liu T, Bei Q, Xu S*. Comprehensive landscape of ovarian cancer immune microenvironment base on multi-omics integration analysis. Front Oncol. 2021; 11: 685065.
6. Xu F, Shen J, Xu S*. Multi-omics Data Analyses Construct a Six Immune-Related Genes Prognostic Model for Cervical Cancer in Tumor Microenvironment. Front Genet. 2021; 12: 663617.
7. Xu F, Shen J, Xu S*. Integrated Bioinformatical Analysis Identifies GIMAP4 as an Immune-Related Prognostic Biomarker Associated with Remodeling in Cervical Cancer Tumor Microenvironment. Front Cell Dev Biol. 2021; 9:637400.
8. Dai Y, Cao Y, Kohler J, Lu A, Xu S*, Wang H*. Unbiased RNA-Seq-driven identification and validation of reference genes for quantitative RT-PCR analyses of pooled cancer exosomes. BMC Genomics. 2021; 22(1):27.
9. Li S#, Li Q#, Lu J, Zhao Q, Li D, Shen L, Wang Z, Liu J, Xie D, Cho William C, Xu S*, Yu Z*. Targeted Inhibition of miR-221/222 Promotes Cell Sensitivity to Cisplatin in Triple-Negative Breast Cancer MDA-MB-231 Cells. Front Genet. 2020; 10: 1278-1278.
10. Tao Z#, Xu S#, Ruan H, Wang T, Song W, Qian L, Chen K*. MiR-195/-16 Family Enhances Radiotherapy via T Cell Activation in the Tumor Microenvironment by Blocking the PD-L1 Immune Checkpoint. Cell Physiol Biochem. 2018; 48(2):801-814.
11. Xu S#, Tao Z#, Hai B, Liang H, Shi Y, Wang T, Song W, Chen Y, Ou Y, Chen J, Kong F, Dong Y, Jiang S, Li W, Wang P, Yuan Z, Wan X, Wang C, Li W, Zhang X, Chen K*. miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint. Nat Commun. 2016; 5(7):11406.
12. Xu S#, Fu G#, Tao Z, Ou Y, Kong F, Jiang B, Wan X, Chen K*. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1. Oncotarget. 2015; 28:26457-71.
13. Xu S, Wang T, Song W, Jiang T, Zhang F, Yin Y, Jiang S, Wu K, Yu Z, Wang C, Chen K*. The inhibitory effects of AR/miR- 190a/YB-1 negative feedback loop on prostate cancer and underlying mechanism. Sci Rep. 2015; 5:13528.
14. Xu S, Xu P, Wu W, Ou Y, Xu J, Zhang G, Li J, Xu G*. The biphasic expression pattern of miR-200a and E-cadherin in epithelial ovarian cancer and its correlation with clinicopathological features. Curr Pharm Des. 2014; 20:1888–1895.
15. Xu S, Ren J, Chen H, Wang Y, Liu Q, Zhang R, Jiang S, Li J*. Cytostatic and Apoptotic Effects of DNMT and HDAC Inhibitors in Endometrial Cancer Cells. Curr Pharm Des. 2014; 20(11):1881-7.
16. Xu S, Wu W, Sun H, Lu J, Yuan B, Xia Y, Moor B, Marcha K, Wang X, Xu P, Cheng W*. Association of the Vascular Endothelial Growth Factor Gene Polymorphisms (–460C/T, +405G/C and +936T/C) with Endometriosis: A Meta-Analysis. Ann Hum Genet. 2012; 76:464-71.
17. He J, Wang M, Jiang Y, Chen Q, Xu S, Xu Q, Jiang B*, Liu L*. Chronic Arsenic Exposure and Angiogenesis in Human Bronchial Epithelial Cells via the ROS/miR-199a-5p/HIF-1α/COX-2 Pathway. Environ Health Perspect. 2014; 122(3):255-61.
18. Wang T, Liu Z, Guo S, Wu L, Li M, Yang J, Chen R, Xu H, Cai S, Chen H, Li W, Wang L, Hu Z, Zhuang Q, Xu S, Wang L, Liu J, Ye Z, Ji J, Wang C, Chen K*. The tumor suppressive role of CAMK2N1 in castration-resistant prostate cancer. Oncotarget, 2014; 5(11):3611-3621.
19. Wang T, Guo S, Liu Z, Wu L, Li M, Yang J, Chen R, Liu X, Xu H, Cai S, Chen H, Li W, Xu S, Wang L, Hu Z, Zhuang Q, Wang L, Wu K, Liu J, Ye Z, Ji J, Wang C, Chen K*. CAMK2N1 inhibits prostate cancer progression through androgen receptor-dependent signaling. Oncotarget. 2014; 5(2):10293-10306.
20. Sun X, Jiang S, Liu J, Wang H, Zhang Y, Tang S, Wang J, Du N, Xu C, Wang C, Qin S, Zhang J, Liu D, Zhang Y, Li X, Wang J, Dong J, Wang X, Xu S, Tao Z, Xu F, Zhou J, Wang T, Ren H*. MiR-208a stimulates the cocktail of SOX2 and β-catenin to inhibit the let-7 induction of self-renewal repression of breast cancer stem cells and formed miR208a/let-7 feedback loop via LIN28 and DICER1. Oncotarget. 2015; 6(32):32944-54.
21. Xu C, Sun X, Qin S, Wang H, Zheng Z, Xu S, Luo G, Liu P, Liu J, Du N, Zhang Y, Liu D, Ren H*. Let-7a regulates mammosphere formation capacity through Ras/NF-κB and Ras/MAPK/ERK pathway in breast cancer stem cell. Cell cycle. 2015; 14(11):1686-97.
22. Chen K, Wu K*, Jiao X, Wang L, Ju X, Wang M, Di Sante, G, Xu S, Wang Q, Li KV, Sun X, Xu C, Li Z, Casimiro, MC, Ertel A, Addya S, McCue PA, Lisanti MP, Wang C, Davis RJ, Mardon G, Pestell RG*. The Endogenous Cell-Fate Factor Dachshund Restrains Prostate Epithelial Cell Migration via Repression of Cytokine Secretion via a CXCL Signaling Module. Cancer Research. 2015; 75(10):1992-2004.
23. Sun X, Xu C, Tang S C, Wang J, Wang H, Wang P, Du N, Qin S, Li G, Xu S, Tao Z, Liu D, Ren H*. Let-7c blocks estrogen-activated Wnt signaling in induction of self-renewal of breast cancer stem cells. Cancer Gene Ther. 2016; 23(4): 83-9.
24. Zhu L, Zhang W, Yang X, Cui L, Li J, Zhang Y, Wang Y, Ao J, Ma M, Lu H, Ren Y, Xu S, Yang G, Song W, Wang J, Zhang X, Zhang R*, Zhang Z*. Silencing of MICAL-L2 suppresses malignancy of ovarian cancer by inducing mesenchymal-epithelial transition. Cancer Lett. 2015; 363:71-82.
